Skip to main content
News > News > Bacterial Robotics Briefs Exclusive Group in Bangalore, India, About BactoBots™

Bacterial Robotics Briefs Exclusive Group in Bangalore, India, About BactoBots™

American Consulate General brings together group of representatives from India Government and Industry to gain briefing into locally controlled synthetic biology opportunities

CINCINNATI, OH, USA – January 17, 2013 – CINCINNATI, OH, USA and BANGALORE, INDIA – January 17, 2012 – Bacterial Robotics, a synthetic biology company developing microscopic BactoBots™ announces its visit to Bangalore India. The Company will provide an exclusive presentation and meetings with select professionals invited by the U.S. Commercial Service (Bangalore) of the American Consulate General, Chennai.

This briefing is conducted in conjunction with the Institute of Electrical and Electronics Engineers (IEEE), Engineering in Medicine and Biology Society (EMBS), Point-Of-Care Healthcare Technologies (POCHT) Conference in Bangalore, India, 18 January 2013.

Bacterial Robotics, CEO, Jason E. Barkeloo, will discuss potential industry applications of microscopic “programmable organism-based robots” known as BactoBots. The briefing will cover the planned offerings from the subsidiaries Pilus Energy and Auricle Solutions. The select Invitees will also gain a briefing on how India-based licensees may profit from the local manufacture and distribution of BactoBots.

Mr. Barkeloo will focus specifically on the RemediBot™ and the GalvaniBot™-powered electrogenic bioreactor (EBR) wastewater-to-value proposition offered by Pilus Energy.

Accompanying Mr. Barkeloo is the Chief Medical Officer of Auricle Solutions. As part of the IEEE conference, the attendees will gain an overview of the potential surgical application of the AuriBot™. AuriBot, in tandem with other robotic technologies, will be used in conjunction with standard surgical techniques to eradicate cholesteatomas and chronic otitis media, preventing potential life-threatening complications and deafness. Among points of interest being covered are clinical education and product development collaboration opportunities within India.

When? 18 January 2013, 2-4pm (1400-1600).

Where? Jupiter 1 room, Sheraton (hotel) Bangalore at Brigade Gateway

Why? Besides creating jobs and economic growth, the attendees will gain insights into controlling the launch of a new synthetic biology industry within India. The attendees will be introduced to BactoBots and how to profitably control the distribution of India-manufactured BactoBots. Discussions will include how to develop a BactoBot manufacturing and supply chain industry within India. Through a unique licensing model based upon International and Indian patent filings, Bacterial Robotics’ is working to enable a BactoBot synthetic biology industry in India, controlled by Indians, for Indians.

What Else? The Institute of Electrical and Electronics Engineers (IEEE), Engineering in Medicine and Biology Society (EMBS), Special Topic Conference on Point-Of-Care (POC) Healthcare Technologies Conference, Bangalore, India, is January 16-18, 2013, at the Sheraton Bangalore at Brigade Gateway. Additional information and guidance on registration is at

*pdf version of this release

About Bacterial Robotics

An early developer in the emerging synthetic biology industry, Bacterial Robotics is headquartered in Cincinnati, Ohio (USA). The Company specializes in identifying markets for developing and deploying BactoBots™ and ViruBots™; microscopic organism-based robots that produce, build, sense, and perform functions.

The Company’s products are protected by a proprietary genetics rights management (GeRM™) key system. The GeRM system is a consumable additive that prevents the BactoBots against theft and environmental release. The GeRM enables the Company to gain licensing revenues from the manufacture and distribution of its BactoBots.

Once Bacterial Robotics develops a BactoBot, it creates a go-to-market subsidiary to launch the product. Pilus Energy (wastewater-to-value) and Auricle Solutions (tumor eradication) are the current subsidiaries.

For more information on Bacterial Robotics, visit its web site.


Jason E. Barkeloo
CEO +1.513.225.8765
Twitter: @BactoBot

We Believe

Open Therapeutics crowdsources orphan and dormant therapeutic intellectual properties (IP) to scientists around the world. The goal is advancing research that ordinarily has not generated a public value or been recognized. This approach particularly helps underserved scientists to collaborate with their more financially capable colleagues.

How open science helps researchers succeed:

Open access, open data, open source, and other open scholarship practices are growing in popularity and necessity. However, widespread adoption of these practices has not yet been achieved. One reason is that researchers are uncertain about how sharing their work will affect their careers.

The review of the literature demonstrates that open science is associated with increases in citations, media attention, potential collaborators, job opportunities, and funding opportunities. These findings are evidence that open science practices bring significant benefits to researchers relative to more traditional closed practices.

Secured By miniOrange